论文部分内容阅读
目的 :观察莫沙必利缓解胃食管反流症状和治疗反流性食管炎的疗效。方法 :84例反流性食管炎病人 ,其中莫沙必利组 5 3例 (男性 36例 ,女性17例 ,年龄 4 3a±s 8a) ,给莫沙必利 5mg ,po ,qid ;奥美拉唑组 31例 (男性 18例 ,女性 13例 ,年龄 4 1a± 6a) ,给奥美拉唑 2 0mg ,po ,bid。 8wk后观察治疗前后症状积分及食管炎程度的变化 ,用t检验进行统计处理。结果 :莫沙必利组治疗 8wk后主要临床症状积分为 14 .1分± 0 .9分 ,食管炎程度积分为1.4分± 0 .7分 ,与治疗前 (6 6分± 5分 ,2 .8分±0 .6分 )相比 ,差异均有非常显著意义 (P <0 .0 1) ;与奥美拉唑组相比 ,差异无显著意义 (P >0 .0 5 )。结论 :莫沙必利能明显地缓解胃食管反流症状 ,治疗反流性食管炎疗效较好 ,并能治愈或减轻内镜下食管炎程度。
Objective: To observe the efficacy of Mosapride in relieving gastroesophageal reflux symptoms and treating reflux esophagitis. Methods: A total of 84 patients with reflux esophagitis were enrolled in this study. Among them, 53 patients (36 males, 17 females, age 4 3a ± s 8a) received mosapride 5 mg, po, qid, There were 31 patients in the prazosin group (18 males and 13 females, age 4 1a ± 6a), and omeprazole 20 mg, po, bid. 8wk after treatment before and after treatment to observe the symptom score and the degree of esophagitis changes, using t test for statistical analysis. Results: The scores of main clinical symptoms of mosapride group after treatment for 8 weeks were 14.1 ± 0.9 and the score of esophagitis was 1.4 ± 0. 7, which was significantly higher than that before treatment (6 6 ± 5, 2 .8 points ± 0.6 points), the difference was significant (P <0.01). Compared with the omeprazole group, the difference was not significant (P> 0.05). Conclusion: Mosapride can relieve the symptom of gastroesophageal reflux obviously, treat reflux esophagitis better, and can cure or reduce the degree of endoscopic esophagitis.